{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:53:25Z","timestamp":1790679205776,"version":"4.1.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"1118","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":1521,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fabry disease is a rare inborn error of the enzyme \u03b1-galactosidase (\u03b1-Gal) and results in lysosomal substrate accumulation in tissues with a wide range of clinical presentations. The disease has attracted a lot of interest over the last years, in particular since enzyme replacement therapy (ERT) has become widely available in 2001. With rising awareness and rising numbers of (diagnosed) patients, physicians encounter new challenges. Over 900 \u03b1-Gal gene mutations are currently known, some with doubtful clinical significance, posing diagnostic and prognostic difficulties for the clinician and a lot of uncertainty for patients. Another challenge are patients who develop neutralising antibodies to ERT, which possibly leads to reduced therapy effectiveness. In this article, we summarise the latest developments in the science community regarding diagnostics and management of this rare lysosomal storage disorder and offer an outlook to future treatments.<\/jats:p>","DOI":"10.1136\/postgradmedj-2018-136056","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T22:16:54Z","timestamp":1545085014000},"page":"709-713","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":38,"title":["Hot topics in Fabry disease"],"prefix":"10.1093","volume":"94","author":[{"given":"Tereza","family":"Cairns","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Divisions of Nephrology and Cardiology, University Hospital W\u00fcrzburg , W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"M\u00fcntze","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Divisions of Nephrology and Cardiology, University Hospital W\u00fcrzburg , W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Gernert","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Divisions of Nephrology and Cardiology, University Hospital W\u00fcrzburg , W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Spingler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Divisions of Nephrology and Cardiology, University Hospital W\u00fcrzburg , W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nordbeck","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Divisions of Nephrology and Cardiology, University Hospital W\u00fcrzburg , W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Divisions of Nephrology and Cardiology, University Hospital W\u00fcrzburg , W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,12,17]]},"reference":[{"key":"2023041308045053600_","first-page":"113","article-title":"Fabry disease: molecular genetics of the inherited nephropathy","volume":"18","author":"Desnick","year":"1989","journal-title":"Adv Nephrol Necker Hosp"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10545-017-0098-3","article-title":"Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy","volume":"41","author":"Burlina","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","article-title":"High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population","volume":"2","author":"Lin","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/jhg.2013.48","article-title":"Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study","volume":"58","author":"Inoue","year":"2013","journal-title":"J Hum Genet"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","article-title":"Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria","volume":"379","author":"Mechtler","year":"2012","journal-title":"The Lancet"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/diseases5020015","article-title":"Biomarkers and imaging findings of anderson\u2013Fabry Disease\u2014what we know now","volume":"5","author":"Beir\u00e3o","year":"2017","journal-title":"Diseases"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.ejhg.5201184","article-title":"Remarkable variability in renal disease in a large Slovenian family with Fabry disease","volume":"12","author":"Verovnik","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural history of Fabry disease in females in the Fabry Outcome Survey","volume":"43","author":"Deegan","year":"2006","journal-title":"J Med Genet"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study","volume":"28","author":"Arends","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry\u2019s disease","volume":"372","author":"Zarate","year":"2008","journal-title":"The Lancet"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cca.2018.02.021","article-title":"Functional and pharmacological evaluation of novel GLA variants in Fabry disease identifies six (two de novo) causative mutations and two amenable variants to the chaperone DGJ","volume":"481","author":"Ferri","year":"2018","journal-title":"Clinica Chimica Acta"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"e0173358","DOI":"10.1371\/journal.pone.0173358","article-title":"Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies","volume":"12","author":"El Dib","year":"2017","journal-title":"PLoS One"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmg.2009.072116","article-title":"Screening for Fabry disease in high-risk populations: a systematic review","volume":"47","author":"Linthorst","year":"2010","journal-title":"J Med Genet"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","article-title":"Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \"Kidney Disease: Improving Global Outcomes\" (KDIGO) Controversies Conference","volume":"91","author":"Schiffmann","year":"2017","journal-title":"Kidney Int"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"e0166484","DOI":"10.1371\/journal.pone.0166484","article-title":"Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease","volume":"11","author":"\u00dc\u00e7eyler","year":"2016","journal-title":"PLoS One"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08035320510028111","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatrica"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/gim.2013.56","article-title":"Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa","volume":"15","author":"Schiffmann","year":"2013","journal-title":"Genet Med"},{"key":"2023041308045053600_","article-title":"Detecton of blood Gb3 deposits as a new tool for diagnosis and therapy monitoring in patients with classic Fabry disease","author":"Uceyler","year":"2018","journal-title":"J Intern Med"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/cge.13237","article-title":"The D313Y genotype-Pathogenic mutation or polymorphism?","volume":"93","author":"Oder","year":"2018","journal-title":"Clin Genet"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023041308045053600_","article-title":"Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis","author":"Maruyama","journal-title":"Genet Med"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol Genet Metab"},{"key":"2023041308045053600_","first-page":"70","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"2011","author":"van Breemen","year":"1812","journal-title":"Biochim Biophys Acta"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","article-title":"Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy","volume":"22","author":"Sakuraba","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"27333","DOI":"10.18632\/oncotarget.25542","article-title":"A pilot study of circulating microRNAs as potential biomarkers of Fabry disease","volume":"9","author":"Cammarata","year":"2018","journal-title":"Oncotarget"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2174\/092986712800784739","article-title":"Novel gb(3) isoforms detected in urine of fabry disease patients: a metabolomic study","volume":"19","author":"Auray-Blais","year":"2012","journal-title":"Curr Med Chem"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s13361-014-1060-3","article-title":"Metabolomic discovery of novel urinary galabiosylceramide\u2009analogs as Fabry disease biomarkers","volume":"26","author":"Boutin","year":"2015","journal-title":"J Am Soc Mass Spectrom"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3109\/0886022X.2010.516859","article-title":"Study of urinary proteomes in Anderson-Fabry disease","volume":"32","author":"Vojtov\u00e1","year":"2010","journal-title":"Ren Fail"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1039\/C4MB00707G","article-title":"Early markers of Fabry disease revealed by proteomics","volume":"11","author":"Matafora","year":"2015","journal-title":"Mol Biosyst"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/HCO.0000000000000308","article-title":"Fabry disease: will markers of early disease enable early treatment and better outcomes?","volume":"31","author":"Hughes","year":"2016","journal-title":"Curr Opin Cardiol"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000448968","article-title":"Long term treatment with enzyme replacement therapy in patients with Fabry Disease","volume":"134","author":"Oder","year":"2016","journal-title":"Nephron"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"Jama"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/GIM.0b013e318170f868","article-title":"Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme","volume":"10","author":"Bodensteiner","year":"2008","journal-title":"Genet Med"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","article-title":"Anti-\u03b1-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry","volume":"105","author":"Wilcox","year":"2012","journal-title":"Mol Genet Metab"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"B\u00e9nichou","year":"2009","journal-title":"Mol Genet Metab"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-mediated inhibition of enzyme replacement therapy in Fabry Disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/8904_2015_483","article-title":"Reduction of plasma globotriaosylsphingosine levels after switching from agalsidase alfa to agalsidase beta as enzyme replacement therapy for Fabry Disease","volume":"25","author":"Goker-Alpan","year":"2016","journal-title":"JIMD Rep"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.jaci.2017.12.1001","article-title":"Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion","volume":"141","author":"Lenders","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.beem.2015.01.006","article-title":"The role of antibodies in enzyme treatments and therapeutic strategies","volume":"29","author":"Bigger","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/joim.12647","article-title":"Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease","volume":"282","author":"Lenders","year":"2017","journal-title":"J Intern Med"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/cpdd.1","article-title":"Pharmacokinetics and Safety of Migalastat HCl and Effects on Agalsidase Activity in Healthy Volunteers","volume":"2","author":"Johnson","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet Med"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J Med Genet"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/eurheartj\/ehy072","article-title":"Treatment of hypertrophic cardiomyopathy caused by cardiospecific variants of Fabry disease with chaperone therapy","volume":"39","author":"M\u00fcntze","year":"2018","journal-title":"Eur Heart J"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"e0134341","DOI":"10.1371\/journal.pone.0134341","article-title":"Oral Migalastat HCl leads to greater systemic exposure and tissue levels of active \u03b1-galactosidase A in Fabry patients when co-administered with infused agalsidase","volume":"10","author":"Warnock","year":"2015","journal-title":"PLoS One"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bcmd.2013.04.005","article-title":"Miglustat therapy in type 1 Gaucher disease: Clinical and safety outcomes in a multicenter retrospective cohort study","volume":"51","author":"Kuter","year":"2013","journal-title":"Blood Cells Mol Dis"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cpt.790","article-title":"Lucerastat, an iminosugar for substrate reduction therapy: Tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry Disease on Enzyme Replacement","volume":"103","author":"Gu\u00e9rard","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/1566523218666180404161315","article-title":"Genetics and gene therapy of Anderson-Fabry Disease","volume":"18","author":"Simonetta","year":"2018","journal-title":"Curr Gene Ther"},{"issue":"Suppl 2","key":"2023041308045053600_","article-title":"Advances in gene therapy for hemophilia: basis, current status, and future perspectives","volume":"2012","author":"Ohmori","year":"2018","journal-title":"Int J Hematol"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/1097-0142(20010401)91:7<1231::AID-CNCR1123>3.0.CO;2-K","article-title":"The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience","volume":"91","author":"Chang","year":"2001","journal-title":"Cancer"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","DOI":"10.3390\/diseases6030069","article-title":"The importance of a multidisciplinary approach in the management of a patient with type I Gaucher Disease","volume":"6","author":"Torralba-Cabeza","year":"2018","journal-title":"Diseases"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European expert consensus statement on therapeutic goals in Fabry disease","volume":"124","author":"Wanner","year":"2018","journal-title":"Mol Genet Metab"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"e0120814","DOI":"10.1371\/journal.pone.0120814","article-title":"Ocular signs correlate well with disease severity and genotype in Fabry disease","volume":"10","author":"Pitz","year":"2015","journal-title":"PLoS One"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.2174\/13816128113199990359","article-title":"Cutaneous complications of Anderson-Fabry disease","volume":"19","author":"Giuseppe","year":"2013","journal-title":"Curr Pharm Des"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.2174\/13816128113199990387","article-title":"Neurological complications of Anderson-Fabry disease","volume":"19","author":"Tuttolomondo","year":"2013","journal-title":"Curr Pharm Des"},{"key":"2023041308045053600_","first-page":"38","article-title":"Cardiac abnormalities in Anderson-Fabry disease and Fabry\u2019s cardiomyopathy","volume":"22","author":"Morrissey","year":"2011","journal-title":"Cardiovasc J Afr"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2369-15-72","article-title":"Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?","volume":"15","author":"Waldek","year":"2014","journal-title":"BMC Nephrol"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/1756283X16642936","article-title":"Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis","volume":"9","author":"Zar-Kessler","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13023-018-0882-7","article-title":"Characterization of vertigo and hearing loss in patients with Fabry disease","volume":"13","author":"K\u00f6ping","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"2023041308045053600_","doi-asserted-by":"crossref","first-page":"26721","DOI":"10.3402\/ecrj.v2.26721","article-title":"Fabry disease, respiratory symptoms, and airway limitation \u2013 a systematic review","volume":"2","author":"Svensson","year":"2015","journal-title":"Eur Clin Respir J"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/94\/1118\/709\/49812103\/postgradmedj-94-709.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/94\/1118\/709\/49812103\/postgradmedj-94-709.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T07:06:01Z","timestamp":1694502361000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/94\/1118\/709\/6959231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":65,"journal-issue":{"issue":"1118","published-online":{"date-parts":[[2018,12,17]]},"published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1136\/postgradmedj-2018-136056","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12]]},"published":{"date-parts":[[2018,12,1]]}}}